Game-changing immunotherapy drug DOUBLES head and neck cancer survival rates 



A breakthrough immunotherapy drug has been proved to double survival rates for head and neck cancer.
Nivolumab, developed by the Institute of Cancer Research, is the first treatment to extend survival in a phase III clinical trial for patients who did not respond to chemotherapy.
And there were far fewer side effects than most aggressive tumor-fighting medications. 
It has been hailed as a game-changer for the notoriously difficult-to-treat disease strains.
WHY IS HEAD AND NECK CANCER HARD TO TREAT?  Head and neck cancer are the sixth most common strains of the disease globally.
It covers... read more

 
10 October 2016 in Health, Views: 39
Source: Daily Mail
Share:
  •  





    News Widget for Webmasters



    Bring Eugene's son back home immediately

    Realtime News

     

    «
    »
    Mo Tu We Th Fr Sa Su
          1 2 3 4
    5 6 7 8 9 10 11
    12 13 14 15 16 17 18
    19 20 21 22 23 24 25
    26 27 28 29 30 31